信达生物与ImmVirX拓展临床合作,将评估信迪利单抗联合IVX037溶瘤病毒治疗晚期肝癌的效果。正在进行的Ib期研究已启动患者入组,计划新增研究中心并增加15例肝癌患者。双方对此次合作及研究前景表示期待。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.